Relative Sensitivity: 96.97% (95% CI:83.35% ~99.99%)
Kunyatsoenderana: 100.00% (95% CI:97.29% ~100.00%)
Kunyatsoita: 99.50% (95%CI:96.94% ~99.99%)
Inokurumidza mhedzisiro mu15-30 maminetsi Rapid antigen kit AMRDT120
Muedzo wekukurumidza wehutano hwekuonekwa kwe neutralizing
masoja ekudzivirira chirwere kuSARS-CoV-2 kana majekiseni ayo muropa rakazara, serum, kana plasma.
Package Tsanangudzo: 40 T/kiti, 20 T/kiti, 10 T/kiti, 1 T/kiti.
Relative Sensitivity: 96.97% (95% CI:83.35% ~99.99%)
Kunyatsoenderana: 100.00% (95% CI:97.29% ~100.00%)
Kunyatsoita: 99.50% (95%CI:96.94% ~99.99%)
Foil pouches, ine test cassttes uye desiccants *20
Assay buffer *20 mabhodhoro;
Madonhwe anoraswa *20;
Lancet *20
Lodine swab*20
Murairo wekushandisa*1
Kurumidza kunoguma mu15-30 maminetsi Rapid antigen kit AMRDT120 YARIKUDA KUSHANDISA.
Iyo SARS-CoV-2 Neutralizing Antibody Rapid Test (COVID-19 Ab) inokurumidza chromatographic immunoassay yemhando yekuonekwa kwekusarerekera masoja ekudzivirira chirwere kuSARS-CoV-2 muropa rakazara, serum, kana plasma.
Inokurumidza mhedzisiro mu15-30 maminetsi Rapid antigen kit AMRDT120 PRINCIPLE
Iyo SARS-CoV-2 Neutralizing Antibody Rapid Test (COVID-19 Ab) ndeyekuona masoja ekudzivirira chirwere kuSARS-CoV-2 kana majekiseni ayo.Iyo cell surface receptor angiotensin inoshandura enzyme-2 (ACE2) yakaputirwa munharaunda yekuyedza uye iyo recombinant receptor-binding domain (RBD) yakasanganiswa neanoratidza zvidimbu.
Munguva yekuyedzwa, kana paine SARS-CoV-2 neutralizing masoja ekudzivirira chirwere mumuenzaniso, yaizoita neprotein RBD-particle conjugate uye isingaite nepre-coated protein ACE2.Musanganiswa wacho unobva wasimuka uchienda kumusoro pa membrane chromatographically ne capillary action uye yaisazobatwa ne pre-coated antigen.Iyo SARS-CoV-2 Neutralizing Antibody Rapid Test (COVID-19 Ab) ine mapuroteni RBD-akavharwa zvimedu.Iprotein ACE2 yakavharwa munharaunda yebvunzo.
